Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1 Study of Durvalumab, Tremelimumab and Radiotherapy in Recurrent Gynecologic Cancer

NCT03277482 is registered in ClinicalTrials.gov with Dana-Farber Cancer Institute as lead sponsor.

NCT NCT03277482
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03277482 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1 Study of Durvalumab, Tremelimumab and Radiotherapy in Recurrent Gynecologic Cancer
Lead sponsor
Dana-Farber Cancer Institute
Phase
Phase 1
Overall status
Terminated
Start date
June 1, 2018
Completion date
July 15, 2022
Enrollment
16 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic cervical cancer, metastatic endometrial cancer, metastatic ovarian cancer, metastatic vaginal cancer, metastatic vulvar cancer, recurrent cervical carcinoma, recurrent endometrial cancer, recurrent gynecological cancer, recurrent ovarian carcinoma, recurrent vaginal cancer, recurrent vulvar cancer